PharmaLundensis
Sweden - LundBiotechnology
Focus: PharmaLundensis is a Swedish biotech specializing in heavy metal chelation therapies and radiopharmaceuticals for neurological applications. The company operates at pre-revenue to early-stage commercialization with a focused, niche product portfolio.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Open Jobs
0
About PharmaLundensis
AI assessmentNot HiringNo open roles listed right now. Follow PharmaLundensis to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Selenomethionine SE-75
Stable
Pre-Launch
Radiopharmaceutical diagnostic with pre-launch status; earliest commercialization candidate in portfolio.
Hippuran I-131
Help build intelligence for PharmaLundensis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.